D L Carlson Investment Group Inc. Invests $559,000 in Repligen Corporation $RGEN

D L Carlson Investment Group Inc. acquired a new position in shares of Repligen Corporation (NASDAQ:RGEN) in the 2nd quarter, HoldingsChannel.com reports. The firm acquired 4,098 shares of the biotechnology company’s stock, valued at approximately $559,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Measured Wealth Private Client Group LLC acquired a new stake in Repligen in the third quarter valued at approximately $29,000. Bayforest Capital Ltd acquired a new position in shares of Repligen during the fourth quarter worth $32,000. Rachor Investment Advisory Services LLC acquired a new position in shares of Repligen during the fourth quarter worth $33,000. Los Angeles Capital Management LLC purchased a new stake in shares of Repligen during the 4th quarter valued at $36,000. Finally, Farther Finance Advisors LLC lifted its holdings in shares of Repligen by 61.8% during the 4th quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 128 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on RGEN. Citigroup upgraded Repligen to a “buy” rating in a research note on Tuesday, July 7th. Barclays increased their price target on Repligen from $145.00 to $160.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. Royal Bank Of Canada initiated coverage on Repligen in a report on Thursday, May 14th. They issued an “outperform” rating and a $160.00 price target for the company. Weiss Ratings upgraded Repligen from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, August 13th. Finally, Benchmark raised shares of Repligen from a “hold” rating to a “buy” rating and set a $185.00 price objective for the company in a research report on Tuesday, July 7th. Three analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $166.43.

Repligen Stock Up 2.2%

Repligen stock opened at $180.29 on Friday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.64 and a current ratio of 9.05. The business’s 50-day simple moving average is $146.14 and its two-hundred day simple moving average is $131.54. The company has a market cap of $10.18 billion, a PE ratio of 246.97, a PEG ratio of 3.22 and a beta of 1.03. Repligen Corporation has a fifty-two week low of $100.99 and a fifty-two week high of $188.73.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share for the quarter, beating analysts’ consensus estimates of $0.45 by $0.09. Repligen had a return on equity of 5.30% and a net margin of 5.29%.The business had revenue of $204.13 million for the quarter, compared to analyst estimates of $201.59 million. During the same period in the prior year, the company earned $0.26 earnings per share. The company’s revenue was up 11.9% on a year-over-year basis. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. Equities analysts anticipate that Repligen Corporation will post 2.06 EPS for the current year.

Insiders Place Their Bets

In related news, CFO Jason K. Garland sold 733 shares of the stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $145.00, for a total value of $106,285.00. Following the transaction, the chief financial officer owned 19,359 shares in the company, valued at approximately $2,807,055. This represents a 3.65% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.60% of the company’s stock.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.